Cost-utility analysis studies of depression management: A systematic review

被引:49
|
作者
Pirraglia, PA
Rosen, AB
Hermann, RC
Olchanski, NV
Neumann, P
机构
[1] Brown Univ, Sch Med, Rhode Isl Hosp, Div Gen Internal Med, Providence, RI 02903 USA
[2] Harvard Univ, Sch Publ Hlth, Harvard Ctr Risk Anal, Program Econ Evaluat Med Technol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02115 USA
[4] Tufts Univ New England Med Ctr, Hlth Inst, Dept Psychiat, Boston, MA 02111 USA
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2004年 / 161卷 / 12期
关键词
D O I
10.1176/appi.ajp.161.12.2155
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Depression is common, costly, treatable, and a major influence on quality of life. Cost-utility analysis combines costs with quantity and quality of life into a metric that is meaningful for studies of interventions or care strategies and is directly comparable to measures in other such studies. The objectives of this study were to identify published cost-utility analyses of depression screening, pharmacologic treatment, nonpharmacologic therapy, and care management; to summarize the results of these studies in an accessible format; to examine the analytic methods employed; and to identify areas in the depression literature that merit cost-utility analysis. Method: The authors selected articles regarding cost-utility analysis of depression management from the Harvard Center for Risk Analysis Cost-Effectiveness Registry. Characteristics of the publications, including study methods and analysis, were examined. Cost-utility ratios for interventions were arranged in a league table. Results: Of the 539 cost-utility analyses in the registry, nine (1.7%) were of depression management. Methods for determining utilities and the source of the data varied. Markov models or cohort simulations were the most common analytic techniques. Pharmacologic interventions generally had lower costs per quality-adjusted life year than nonpharmacologic interventions. Psychotherapy alone, care management alone, and psychotherapy plus care management all had lower costs per quality-adjusted life year than usual care. Depression screening and treatment appeared to fall within the cost-utility ranges accepted for common nonpsychiatric medical conditions. Conclusions: There is a paucity of literature on cost-utility analysis of depression management. High-quality cost-utility analysis should be considered for further research in depression management.
引用
收藏
页码:2155 / 2162
页数:8
相关论文
共 50 条
  • [31] Cost-Utility and Cost-Effectiveness Studies of Telemedicine, Electronic, and Mobile Health Systems in the Literature: A Systematic Review
    de la Torre-Diez, Isabel
    Lopez-Coronado, Miguel
    Vaca, Cesar
    Saez Aguado, Jesus
    de Castro, Carlos
    [J]. TELEMEDICINE AND E-HEALTH, 2015, 21 (02) : 81 - 85
  • [32] Methylphenidate in children with hyperactivity: review and cost-utility analysis
    Gilmore, A
    Milne, R
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (02) : 85 - 94
  • [33] Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies
    Kumar, Sajith
    Bagepally, Bhavani Shankara
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, : 1027 - 1040
  • [34] Cost-Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
    Guets, Wilfried
    Al-Janabi, Hareth
    Perrier, Lionel
    [J]. PHARMACOECONOMICS, 2020, 38 (04) : 341 - 356
  • [35] Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
    Thorat, Teja
    Neumann, Peter J.
    Chambers, James D.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 632 - 642
  • [36] Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review
    Sussman, Matthew
    Tao, Charles
    Patel, Pankaj
    Tundia, Namita
    Clewell, Jerry
    Menzin, Joseph
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 610 - 623
  • [37] Cost-utility analyses of drug therapies in breast cancer: a systematic review
    Nerich, Virginie
    Saing, Sopany
    Gamper, Eva Maria
    Kemmler, Georg
    Daval, Franck
    Pivot, Xavier
    Holzner, Bernhard
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 407 - 424
  • [38] The cost-utility of screening for depression in primary care
    Valenstein, M
    Vijan, S
    Zeber, JE
    Boehm, K
    Buttar, A
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (05) : 345 - 360
  • [39] COST-UTILITY ANALYSES OF INTERVENTIONS FOR INFORMAL CAREGIVERS: A SYSTEMATIC AND CRITICAL REVIEW
    Guets, W.
    Al-Janabi, H.
    Perrier, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S711 - S711
  • [40] COST-UTILITY ANALYSIS IN UROLOGY
    Fero, Katherine
    Sharma, Vidit
    Lec, Patrick
    Saigal, Christopher
    Chamie, Karim
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E435 - E436